CEL-SCI Receives Croatian Government Approval to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer

- CEL-SCI Corporation (NYSE: CVM ) announced today that it has received approval from the Health Protection Administration, Ministry of Health, of the Croatian Republic to begin enrollment of subjects into